My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

181.32 +0.57 (+0.32%)

Streaming Delayed Price Updated: 3:07 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

56 57 Next >

The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech ↗

April 14, 2023

One executive called this the most "damaging" decision in five decades.

Via Investor's Business Daily

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...

Via Benzinga

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

April 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement

From Denali Therapeutics Inc.

Via GlobeNewswire

12 Analysts Have This to Say About Biogen ↗

April 11, 2023

Via Benzinga

A Look Into Biogen's Debt ↗

April 03, 2023

Via Benzinga

Price Over Earnings Overview: Biogen ↗

March 31, 2023

Via Benzinga

Biogen Unusual Options Activity ↗

March 23, 2023

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...

Via Benzinga

3 Biotech Stocks to Watch for Potential Breakthroughs ↗

April 11, 2023

These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future.

Via InvestorPlace

Twitter Inc Is Officially Defunct, Alibaba Plans to Integrate ChatGPT Like Chatbot Across Products, Moderna's Flu Shot Study Misses 'Early Success' Criteria: Today's Top Stories ↗

April 11, 2023

Benzinga Twitter Inc Is Officially Defunct As Elon Musk Pursues' Superapp' Goal

Via Benzinga

11 Analysts Have This to Say About Biogen ↗

March 23, 2023

Via Benzinga

Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit ↗

March 21, 2023

Via Benzinga

Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension ↗

April 11, 2023

Via Benzinga

Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket ↗

April 10, 2023

Shares are closing in on a buy point out of a consolidation.

Via Investor's Business Daily

The 3 Best Millionaire-Maker Stocks to Buy for April 2023 ↗

April 07, 2023

These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

April 07, 2023

Via Benzinga

Biogen Appoints Adam Keeney as Head of Corporate Development

April 04, 2023

From Biogen Inc.

Via GlobeNewswire

Tesla Manufactured 4,000 Model Ys In One Week, UBS Prepping For Massive Layoffs, McDonald's Temporary Shuttering Of US Offices: Today's Top Stories ↗

April 03, 2023

Bloomberg UBS Prepping For Massive Layoffs Amid Credit Suisse Takeover

Via Benzinga

National Institute on Aging Aims Building $300M Alzheimer's Research Database ↗

April 03, 2023

The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer...

Via Benzinga

Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug ↗

March 31, 2023

Via Benzinga

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

March 30, 2023

From Biogen Inc.

Via GlobeNewswire

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

March 30, 2023

From Biogen Inc.

Via GlobeNewswire

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

March 29, 2023

From Biogen Inc.

Via GlobeNewswire

7 Blue-Chip Stocks Sitting in the Sweet Spot ↗

March 23, 2023

Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move.

Via InvestorPlace

Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23 ↗

March 23, 2023

Looking for longs after a clear resumption of the uptrend.

Via Talk Markets

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement ↗

March 23, 2023

The companies are focusing on a small population of ALS patients with a genetic mutation.

Via Investor's Business Daily

FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder ↗

March 23, 2023

Via Benzinga

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

March 22, 2023

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States

From Biogen Inc.

Via GlobeNewswire

iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation Is A Breakthrough Three-Pronged Approach ↗

March 22, 2023

Interested in investing in iMetabolic BioPharma? Click here to get started!

Via Benzinga

7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗

March 21, 2023

These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023.

Via InvestorPlace

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.